JSKN016 + capecitabine

JSKN016 + capecitabine is a combination therapy under investigation for the treatment of HER2-expressing solid tumors. JSKN016 is a next-generation bispecific antibody-drug conjugate (ADC) developed by Alphamab Oncology that simultaneously targets two non-overlapping epitopes of the Human Epidermal Growth Factor Receptor 2 (HER2). It is conjugated to a potent topoisomerase I inhibitor payload, which induces DNA strand breaks and apoptosis upon internalization. Capecitabine is an orally administered fluoropyrimidine carbamate that acts as a systemic cytotoxic agent; it is converted to 5-fluorouracil (5-FU) in vivo, which subsequently inhibits thymidylate synthase, thereby disrupting DNA synthesis and repair. The combination aims to provide synergistic anti-tumor activity by combining targeted HER2-mediated delivery of a cytotoxic payload with the broad antimetabolite activity of capecitabine, particularly in patients with advanced breast or gastric cancers who have progressed on prior therapies.

Other names

JSKN016 and capecitabineJSKN-016 and capecitabineJSKN 016 and capecitabineJSKN-016 + capecitabineJSKN016 + Xeloda